Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 8, 2016, Pages 2218-2229

  Walsh, Clare C ^a   Landersdorfer, Cornelia B ^a   McIntosh, Michelle P ^a   Peleg, Anton Y ^a   Hirsch, Elizabeth B ^b   Kirkpatrick, Carl M ^a   Bergen, Phillip J ^a  

^a MONASH UNIVERSITY   (Australia)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FOSFOMYCIN; POLYMYXIN B; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; DRUG INTERACTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; FOSFOMYCIN; HUMANS; MICROBIAL VIABILITY; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 84982193759     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw115     Document Type: Article

References (67)

1. Boucher HW, Talbot GH, Benjamin DK et al. 10×'20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56: 1685-94.
2. Bassetti M, Ginocchio F, Mikulska M et al. Will new antimicrobials overcome resistance among Gram-negatives? Expert Rev Anti Infect Ther 2011; 9: 909-22.
3. WHO. Antimicrobial Resistance: Global Report on Surveillance 2014. Geneva. http://www.who.int/drugresistance/documents/surveillancereport/en/.
4. Folkesson A, Jelsbak L, Yang L et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Micro 2012; 10: 841-51.
5. Lu Q, Eggimann P, Luyt C-E et al. Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes. Crit Care 2014; 18: R17.
6. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011; 15: e732-9.
7. Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect 2012; 18: 4-7.
8. Mirakhur A, Gallagher MJ, Ledson MJ et al. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003; 2: 19-24.
9. Falagas M, Kastoris A, Karageorgopoulos D et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009; 34: 111-20.
10. Falagas ME, Maraki S, Karageorgopoulos D et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010; 35: 240-3.
11. Falagas ME, Kastoris A, Kapaskelis A et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50.
12. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014; 15: 1351-70.
13. Forest Pharmaceuticals Inc. Monurol (Fosfomycin) Package Insert. St Louis, MO, USA, 2014.
14. Hendlin D, Stapley EO, Jackson M et al. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science 1969; 166: 122-3.
15. Kahan FM, Kahan J, Cassidy P et al. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974; 235: 364-86.
16. Mengin-Lecreulx D, van Heijenoort J. Correlation between the effects of fosfomycin and chloramphenicol on Escherichia coli. FEMS Microbiol Lett 1990; 54: 129-33.
17. Popovic M, Steinort D, Pillai S et al. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2010; 29: 127-42.
18. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008; 27: 439-43.
19. Florent A, Chichmanian RM, Cua E et al. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents 2011; 37: 82-3.
20. Falagas ME, Giannopoulou KP, Kokolakis GN et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008; 46: 1069-77.
21. Karageorgopoulos DE, Wang R, Yu XH et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012; 67: 255-68.
22. Rodriguez-Rojas A, Macia MD, Couce A et al. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS One 2010; 5: e10193.
23. Walsh CC, McIntosh MP, Peleg AY et al. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 2015; 70: 3042-50.
24. Rodriguez-Rojas A, Couce A, Blazquez J. Frequency of spontaneous resistance to fosfomycin combinedwith different antibiotics in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 4948-9.
25. Pogue JM, Marchaim D, Kaye D et al. Revisiting 'older' antimicrobials in the era of multidrug resistance. Pharmacotherapy 2011; 31: 912-21.
26. Souli M, Galani I, Boukovalas S et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011; 55: 2395-7.
27. Karageorgopoulos DE, Miriagou V, Tzouvelekis LS et al. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 2012; 67: 2777-9.
28. Mouton JW, Ambrose PG, Canton R et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011; 14: 107-17.
29. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
30. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
31. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 5.0, 2015. http://www.eucast.org/clinical_breakpoints/.
32. Traunmüller F, Popovic M, Konz K-H et al. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates. Clin Pharmacokinet 2011; 50: 493-503.
33. Pfausler B, Spiss H, Dittrich P et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomyassociated ventriculitis. J Antimicrob Chemother 2004; 53: 848-52.
34. Sandri AM, Landersdorfer CB, Jacob J et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57: 524-31.
35. Conil JM, Georges B, Ruiz S et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011; 71: 61-71.
36. Geller DE, Pitlick WH, Nardella PA et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219-26.
37. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119: 1114-22.
38. Pillai SK, Moellering RC, Eliopoulos GM. Chapter 9: antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Philadelphia, PA: Lippincott Williams & Wilkins, 2005; 365-440.
39. Bergen PJ, Forrest A, Bulitta JB et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011; 55: 5134-42.
40. Bergen PJ, Tsuji BT, Bulitta JB et al. Synergistic killing of multidrugresistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011; 55: 5685-95.
41. Trapnell BC, McColley SA, Kissner DG et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185: 171-8.
42. Theuretzbacher U, Van Bambeke F, Canton R et al. Reviving old antibiotics. J Antimicrob Chemother 2015; 70: 2177-81.
43. Michalopoulos A, Virtzili S, Rafailidis P et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16: 184-6.
44. Pontikis K, Karaiskos I, Bastani S et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrugresistant and extensively drug-resistant carbapenemase-producing Gramnegative bacteria. Int J Antimicrob Agents 2014; 43: 52-9.
45. Shawar RM, MacLeod DL, Garber RL et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 2877-80.
46. Zhanel GG, Adam HJ, Baxter MR et al. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother 2013; 68 Suppl 1: i7-22.
47. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66: 2070-4.
48. Walkty A, Baxter M, Adam H et al. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained frompatients in Canadian hospitals: CANWARD 2008-2011. Diagn Microbiol Infect Dis 2012; 73: 361-4.
49. Di X, Wang R, Liu B et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomonas aeruginosa. J Antibiot 2015; 68: 551-5.
50. Díez-Aguilar M, Morosini MI, Tedim AP et al. Antimicrobial activity of fosfomycin-tobramycin combination against Pseudomonas aeruginosa isolates assessed by time-kill assays and mutant prevention concentrations. Antimicrob Agents Chemother 2015; 59: 6039-45.
51. MacLeod DL, Velayudhan J, Kenney TF et al. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012; 56: 1529-38.
52. Samonis G, Maraki S, Karageorgopoulos DE et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrugresistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012; 31: 695-701.
53. MacLeod DL, Barker L, Sutherland J et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009; 64: 829-36.
54. Pruekprasert P, Tunyapanit W. In vitro activity of fosfomycingentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa. Southeast Asian J Trop Med Public Health 2005; 36: 1239-42.
55. Mikuniya T, Kato Y, Ida T et al. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 2007; 13: 285-90.
56. Yamada S, Hyo Y, Ohmori S et al. Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa. Chemotherapy 2007; 53: 202-9.
57. Figueredo VM, Neu HC. Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis. J Antimicrob Chemother 1988; 22: 41-50.
58. Cai Y, Fan Y, Wang R et al. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J Antimicrob Chemother 2009; 64: 563-6.
59. Tessier F, Quentin C. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1997; 16: 159-62.
60. Okazaki M, Suzuki K, Asano N et al. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother 2002; 8: 37-42.
61. Fernandez-Olmos A, Garcia-Castillo M, Maiz L et al. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients. Int J Antimicrob Agents 2012; 40: 173-6.
62. Kunakonvichaya B, Thirapanmethee K, Khuntayaporn P et al. Synergistic effects of fosfomycin and carbapenems against carbapenemresistant Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents 2015; 45: 556-7.
63. McCaughey G, Diamond P, Elborn JS et al. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PloS One 2013; 8: e69763.
64. Bulitta JB, Li J, Poudyal A et al. Quantifying synergy of colistin combinations against MDR Gram-negatives by mechanism-based models. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract A1-537, p. 41. American Society for Microbiology, Washington, DC, USA.
65. Landersdorfer CB, Ly NS, Xu H et al. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother 2013; 57: 2343-51.
66. Castañeda-García A, Rodríguez-Rojas A, Guelfo JR et al. The glycerol- 3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J Bacteriol 2009; 191: 6968-74.
67. Lahiri S, Bangaru V, Kumar R et al. A novel mechanism of action for the synergistic antibacterial activity of colistin and fosfomycin. In: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/International Congress of Chemotherapy and Infection (ICC) Annual Meeting, San Diego, CA, 2015. Slide session 150 (C). American Society for Microbiology, Washington, DC, USA.